Status and phase
Conditions
Treatments
About
The study will investigate whether GSK1362885 is safe and well-tolerated when administered to normal healthy subjects. The study will also measure blood levels of the study drug to determine how the body processes the drug (pharmacokinetics) and what effects the drug has on the body (pharmacodynamics).
Full description
GSK1362885 is a glycogen phosphorylase inhibitor that is targeted as a treatment for Type 2 Diabetes Mellitus by reducing hepatic glucose output. This study will investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics when single doses of GSK1362885 are administered to healthy volunteers. A glucagon challenge test will be used to stimulate hepatic glucose output in order to evaluate liver glycogen phosphorylase inhibition by GSK1362885.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
A subject will be eligible for inclusion in this study only if all of the following criteria apply:
Exclusion criteria
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
Other
Primary purpose
Allocation
Interventional model
Masking
42 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal